Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily holds interests in clinical and early-stage pharmaceutical companies and medical devices in the United States and Israel. It operates in three segments: Healthcare, Infusion Technology, and Real Estate. The company develops and commercializes therapies targeting metabolic differences between normal and cancer cells. Its lead drug candidate, Trappsol Cyclo, is in Phase 3 clinical trials for Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. Another candidate, CPI-613 (devimistat), is in Phase II trials. The company is also developing Promitil, a targeted delivery form of mitomycin-C, which has completed Phase 1A and 1B studies in advanced cancers, and surgical devices including an orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.